AngioDynamics, Inc. (ANGO) vs ArriVent BioPharma, Inc. (AVBP)

A side-by-side comparison of AngioDynamics, Inc. and ArriVent BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ANGO

AngioDynamics, Inc.

$597M

$14.43HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT

AVBP

ArriVent BioPharma, Inc.

$691M

$14.83HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT

Total return — ANGO vs AVBP

growth of $100 · dividends reinvested · last 3y

ANGO +165.6% (+38.5%/yr)AVBP +42.3% (+12.5%/yr)ANGO compounded faster over this window

ANGO AVBP

ANGO vs AVBP: by the numbers

•AVBP is the larger company ($691M vs $597M market cap).
•Both run net losses; AVBP's is the smaller (0.00% vs -11.48% net margin).

Metrics side by side

Valuation

Metric	ANGO	AVBP
P/S ratio	1.86	N/A
P/B ratio	3.49	1.88
FCF yield	0.09%	N/A

Profitability

Metric	ANGO	AVBP
Gross margin	54.62%	0.00%
Operating margin	-12.47%	0.00%
Net margin	-11.48%	0.00%
ROE	-21.51%	-44.63%
ROIC	-20.75%	-47.96%

Growth (annualized)

Metric	ANGO	AVBP
Revenue CAGR (5Y)	1.93%	N/A
FCF CAGR (5Y)	-51.49%	N/A
Total return CAGR (5Y)	-10.80%	N/A

Go deeper

Full ANGO analysis Full AVBP analysis Interactive comparison tool

Dig into the metrics

AngioDynamics ROE ArriVent BioPharma ROE AngioDynamics operating margin ArriVent BioPharma operating margin AngioDynamics revenue growth ArriVent BioPharma revenue growth AngioDynamics free cash flow ArriVent BioPharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.